Early research (Phase 1)Study completedNCT02286219
What this trial is testing
Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
Who this might be right for
Solid Tumors That Overexpress HER2 (HER2 Positive)
Bristol-Myers Squibb 30